CryoLife receives CE Mark for HeRo Graft system

CryoLife announced achievement of a CE Mark for the HeRO Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease hemodialysis patients with limited access options and central venous stenosis. The first HeRO Graft clinical cases in Europe are expected to be performed in July. The surgeons performing these initial cases will establish the first HeRO Graft training center in Europe, which will support the company's controlled market introduction of the product during the second half of 2013, followed by a broader European launch in 2014. The company estimates the European market opportunity for the HeRO Graft to be approximately $30M.